Drug Safety

March 17, 2008

New restrictions on anti-anemia drugs

An FDA advisory panel has recommended further strengthening warnings for the use of erythropoiesis-stimulating agents in cancer treatment, according to news reports.

The panel voted to recommend keeping Aranesp (darbepoetin alfa) and Procrit (epoetin alfa) on the market to treat anemia resulting from chemotherapy. But it said they should be given only to patients with incurable cancer and should not be used for those with breast or head and neck cancer. Evidence that the drugs may increase the risks for death and tumor growth led to the new restrictions.

The panel also advised that patients should sign forms indicating that they consent to receive the drugs after being fully informed of the dangers associated with them, according to the New York Times.

The New York Times story may be read here.

March 06, 2008

Heparin contamination

If you or one of your loved ones takes heparin, a blood-thinner often prescribed for patients with heart conditions, you should be watchful for the following symptoms:

  • difficulty breathing
  • nausea
  • vomiting
  • excessive sweating and
  • rapidly falling blood pressure

Continue reading "Heparin contamination" »

March 03, 2008

Avoiding an inappropriate psychiatric hospitalization

Recently, a caregiver complained that a hospital would not allow her to elect a transfer to a psychiatric unit for her parent suffering from dementia. The hospital’s position was that the health care power of attorney did not allow the patient advocate to make a psychiatric admission. They said that only the patient could make that choice. The patient was described as being “delusional.” What seemed probable was that this patient was delirious, not psychotic. If that were the case, then a psychiatric admission would potentially be very harmful to the patient.

Avoiding an inappropriate psychiatric hospitalization for an elderly person can be life-saving for that patient.

Continue reading "Avoiding an inappropriate psychiatric hospitalization" »

February 14, 2008

Heparin warnings

The New York Times reports today that Baxter Healthcare, the manufacturer of about half of the heparin used in the U.S., has stopped making it after hundreds of patients reported severe allergic reactions to the drug. Heparin is a blood thinner widely used in surgery and dialysis. Reportedly, at least four people have died. It's important to note that the complications reported were related to large dosages being injected in patients. Most of the cases were reported in late December or January. 40 percent of the cases were reportedly serious.

Federal regulators say that a shutdown in manufacturing will surely result in shortages of the drug.
Alternative drugs do exist. However, doctors were warned today of serious consequences if heparin becomes truly scarce.

You may read the New York Times article, Problems in Drug Lead to Halt by Factory here.

February 13, 2008

The checklist | A simple way to reduce medical error

Checklist_4

In the December 10, 2008 issue of the New Yorker, author Atul Gawande writes: “If something so simple [as a checklist] can transform intensive care, what else can it do?”

Gawande gives some amazing examples of extraordinary ICU care evolving through the use of checklists. ICU care is complicated. A time and motion study of ICU care in Israel was cited. The study showed that the average ICU patient required 178 individual actions per day, ranging from administering a drug to suctioning the lungs. Any kind of mistake, in the procedure or in the sequence of actions, could result in fatal error.

Continue reading "The checklist | A simple way to reduce medical error" »

January 31, 2008

Speak up and prevent health care errors

Caring at Home has published a valuable article about how seniors can help prevent serious medical errors by paying attention and speaking up when they have questions about their care or the medications prescribed for them.

You can read and reprint this article here.

"To Prevent Health Care Errors, Patients are Urged to SPEAK UP"

December 04, 2007

Commonly prescribed drugs cause most adverse drug events in elders

When I began my research to learn what had caused the death of my mother only 65 days after she had been diagnosed with a simple urinary tract infection, one of my first goals was to learn whether an antipsychotic medication that had been prescribed for her could possibly be linked to her death. I learned that this drug was frequently used in nursing homes to control “behavior problems,” that the drug was intended for use with schizophrenics and that use in the elderly was “off-label” – meaning that the FDA had not approved the drug for that use.

I also learned that research linked use of antipsychotics in the elderly with unacceptable risk of harm to the elderly. In fact, the FDA has since issued a public health advisory to alert health care providers, patients, and patient caregivers to new safety information concerning an unapproved (i.e., “off-label”) use of certain drugs called “atypical antipsychotic drugs.” No research has demonstrated that antipsychotics are effective in “treating” behavioral problems in the elderly. The side effects of antipsychotics make them particularly dangerous to the elderly. These side effects include anorexia, drowsiness, dizziness, and dangerous “extrapyramidal side effects” such as dystonia (Involuntary movements and prolonged muscle contraction resulting in twisting body motions, tremor, and abnormal posture), Parkinsonism (motor stiffness, difficulty initiating movements, shuffling, stiff gait, resting tremors, and reduced facial movements), and others. EPSs can be life-threatening.

Continue reading "Commonly prescribed drugs cause most adverse drug events in elders " »

November 09, 2007

Stronger FDA warnings for Procrit, Epogen, & Aranesp

Additional boxed warnings and label updates for the erythropoiesis-stimulating agents Aranesp, Epogen, and Procrit have been approved by the FDA. Ths issue causing the new warnings relate to drugs dosages that raise hemoglobin levels over 12 g/dL.

Research shows these high dosages stimulated tumor growth and decreased survival in patients with certain cancers: advanced breast, head and neck, lymphoid, and non-small cell lung cancer. It is important to note that researchers have not ruled out higher mortality and tumor progression when hemoglobin rates are raised to levels under 12 g/dL.

Chronic renal failure patients taking these drugs in order to keep hemoglobin levels over 12 g/dL are at increased risk for death, stroke, heart attack, and heart failure. For these patients, the FDA in recommending that hemoglobin levels be maintained between 10 and 12 g/dL.

FDA press release (Free)

Earlier Blog articles related to initial FDA warning, dosing change for erythropoietin

Technorati Tags: Amgen, Epogen, Aranesp

October 29, 2007

Patients & caregivers as partners in care

Jim Conway, chairman of The Partnership for Healthcare Excellence and senior vice president of the Institute for Healthcare Improvement was a featured Op-Ed writer in the Boston Globe on October 29, 2007.

Conway advocates for partnerships between patients, their advocates and the healthcare system. These key points are part of his important message:

Informed, empowered, and engaged patients are key to preventing medical errors and improving the quality of healthcare

Patients who view themselves as partners in their care

  • seek doctors and hospitals who provide quality of care
  • are empowered to ask more questions about their conditions and to more accurately describe their symptoms
  • are better able to comply with treatment regimens because they understand them

What keeps patients from being actively involved in their treatment decisions? Conway says that evidence indicates it’s a lack of knowledge. He says that his partnership is working to empower patients and caregivers by providing them with information on crucial topics such as medication safety, how to choose a doctor or hospital, how to make the most of doctor or hospital visits, etc.

You may read Conway’s editorial, Partnering for better care here.

July 27, 2007

Saving money on prescription medications

Recently, I’ve been exploring Medicare and prescription drug issues. I’ve posted on my blog an article about prescription assistance programs run by drug companies. If you or your loved one are unable to get help from these programs, here’s another way to save money on prescription medications.

Walmart began a program to sell certain generic prescription drugs at the highly discounted price of $4 for a 30-day supply in early October 2006. By the end of 2006, Walmart had expanded this program to all states but one. This includes stores in the Walmart chain (Wal-Mart, Neighborhood Market and Sam’s Club).

Target soon jumped on the bandwagon and began its own $4 generic medication program. It’s easy to see why. Even if a person can’t fill all of his or her prescriptions in this low-cost program, once someone changes pharmacies, it makes sense that they will continue to fill and re-fill prescriptions all in one place.

Continue reading "Saving money on prescription medications" »